Medscape

Medscape InDiscussion: Chronic Myeloid Leukemia

Science EN ↓ 6 episoder

Listen to Medscape InDiscussion: Chronic Myeloid Leukemia, a podcast series where thought leaders and clinical experts share their diverse insights and practical ideas for optimizing patient care. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/989022). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Husk å besøke podkastens nettsted og støtte skaperen: www.medscape.com

Forfatter

Medscape

Kategori

Science

Podkastens nettsted

www.medscape.com

Siste episode

24. okt 2023

Hvor kan du lytte?

Podkaster i appen Replaio Radio Kommer snart

Podkaster kommer snart til appen. Installer nå, og bli den første som ser en helt ny tilnærming til podkaster

Installer gratis Android nesten 10 mill. nedlastinger · 4,8 i vurdering iOS snart

Episoder

What Do We Need To Know About Pregnancy, and Family Planning for Patients Diagnosed With Chronic Myeloid Leukemia? 24.10.2023 26:33

Drs Michael J. Mauro and Jane F. Apperley answer key questions about pregnancy and family planning for patients diagnosed with chronic myeloid leukemia, including complications and treatment options. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/989029). The topics and discussions are planned, produced, and reviewed independently of...

State of the Art Monitoring and Diagnostics in Chronic Myeloid Leukemia: the Philadelphia Chromosome and Future of CML 28.09.2023 20:42

Drs Michael J. Mauro and Jerald P. Radich discuss monitoring and diagnostics in chronic myeloid leukemia, including the Philadelphia chromosome and how it plays into the current treatment of CML. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/989028). The topics and discussions are planned, produced, and reviewed independently of adv...

How Does the History of Chronic Myeloid Leukemia Inform the Future of Diagnosis, Treatment, Resistance, and Cure? 29.08.2023 20:22

Drs Michael J. Mauro and Michael W. Deininger discuss the evolution of chronic myeloid leukemia, better access to treatment, improved global cure rates, and a clearer definition of the word cure. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/989027). The topics and discussions are planned, produced, and reviewed independently of adv...

Developments and Challenges in the Therapeutic Landscape of Chronic Myeloid Leukemia 27.07.2023 20:25

Drs Michael J. Mauro and Jorge E. Cortes discuss developments in the therapeutic landscape of chronic myeloid leukemia, complexities of resistance, and the potential for treatment-free remission. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/989026). The topics and discussions are planned, produced, and reviewed independently of adv...

Targeted Therapy and Evolving Research: Where Are We Winning and Losing in Chronic Myeloid Leukemia? 29.06.2023 18:43

Drs Michael J. Mauro and Ehab Atallah discuss current chronic myeloid leukemia research, where the US stands in comparison with the world, and the important work being conducted by the Cure CML Consortium. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/989025). The topics and discussions are planned, produced, and reviewed independen...

The Cost of Chronic Myeloid Leukemia Therapy, Financial Toxicity, and the Mark Cuban Effect 29.06.2023 23:41

Drs Michael J. Mauro and Hagop Kantarjian discuss the cost of chronic myeloid leukemia therapy, long-term safety, adverse events, and the financial toxicity to the patient and the healthcare system. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/989022). The topics and discussions are planned, produced, and reviewed independently of...